PRAXIS PRECISION MEDICINES, INC. Debt Securities, Available-for-sale, Amortized Cost, Noncurrent
PRAXIS PRECISION MEDICINES, INC. (PRAX) had Debt Securities, Available-for-sale, Amortized Cost, Noncurrent of $12.03 million as of 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent · last filed 2023-02-07
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $12.03M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $31.67M.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $36.51M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost, Noncurrent $48.89M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Noncurrent |
|---|---|
| 2022-03-31 | $12.03M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $31.67M 10-K · filed 2023-02-07 |
| 2021-09-30 | $36.51M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $48.89M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $39.13M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |